Navigation Links
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
Date:2/14/2008

BRISBANE, Calif., Feb. 14 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapeutics, announced that Hoyoung Huh, M.D., Ph.D., has been appointed President and Chief Executive Officer and will commence his new role on March 3, 2008.

Dr. Huh previously served as Chief Operating Officer and Head of the Pegylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG and Roche Holding Ltd. Dr. Huh managed more than 500 employees across global sites in key functions including research, clinical development, manufacturing, marketing and business development. He was also instrumental in establishing multiple new product partnerships and led the acquisition and divestiture of several entities.

Prior to Nektar, Dr. Huh was a partner with McKinsey & Company, serving biotechnology, biopharmaceutical and healthcare clients in the United States, Europe and Asia. He has been an industry thought leader and frequent speaker on topics including licensing, mergers and acquisitions and innovative product development and commercialization strategies. Dr. Huh serves on the board of directors of BayBio, a biotechnology industry association, and Nektar Therapeutics.

"Hoyoung is ideally suited to lead BiPar through this period of expansion and change, with a robust Phase 2 program underway with BSI-201, a potential best-in-class cancer therapy," said G. Kirk Raab, chairman of BiPar, who had served as acting CEO prior to Dr. Huh's appointment. "His business development experience is exceptional, and there is no doubt that Hoyoung will maximize the value of BiPar's programs through rigorous clinical development and well-considered partnerships."

BiPar is developing multiple compounds designed to inhibit PARP-1 (poly-ADP-ribose polymerase), an enzyme crucial to DNA repair that is upregulated in certain tumors. The company's lead compound, BSI-201, has entered a series of Phase 2 trials in tumors types where PARP is overexpressed. The first of those trials will evaluate BSI-201 in patients with "triple negative" breast cancer, and BiPar expects to begin trials in brain and uterine cancers later this quarter.

"BiPar has an extraordinary platform of product candidates, a robust biomarker-driven clinical development plan for its lead program, BSI-201, and an industry-leading management team and board of directors," said Dr. Huh. "I look forward to building BiPar into a leading oncology company by leveraging its exciting product platform in DNA repair."

Dr. Huh received his M.D. and Ph.D. from Cornell University Medical College/Memorial Sloan Kettering Cancer Center and his A.B. from Dartmouth College.

About BiPar Sciences

BiPar Sciences, Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
2. Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
6. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
7. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017 Personal Genome Diagnostics Inc. (PGDx) today ... American Association for Cancer Research (AACR) Annual Meeting 2017, being ... D.C.  The company also announced that five scientists associated with ... th Annual AACR Team Science Award. ... Doug Ward , ...
(Date:3/29/2017)... KING OF PRUSSIA, Pa. , March 29, 2017 ... access to care, which is why CSL Behring awards ... advocacy work of rare disease patient groups. These groups ... patients, voices are heard on Capitol Hill and in ... current funding cycle, the community-based grant was awarded to ...
(Date:3/29/2017)... March 29, 2017 "Surging application of gesture ... the government are expected to drive the growth of ... gesture recognition market is expected to be worth USD ... 29.63% between 2017 and 2022. The touchless sensing market ... 2022, growing at a CAGR of 17.44% between 2017 ...
(Date:3/29/2017)... and PETACH TIKVAH, ... -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a ... for neurodegenerative diseases, announced financial results for ... "2016 was a highly successful and ... achievements and significant progress made on clinical, ...
Breaking Biology Technology:
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
Breaking Biology News(10 mins):